Drug Type Small molecule drug |
Synonyms Emricasan (USAN/INN), IDN-6556, PF-03491390 + [4] |
Target |
Action inhibitors |
Mechanism caspase inhibitors(Caspase inhibitors), Apoptosis inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC26H27F4N3O7 |
InChIKeySCVHJVCATBPIHN-SJCJKPOMSA-N |
CAS Registry254750-02-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Decompensated cirrhosis of liver | Phase 2 | United States | 28 Jun 2017 | |
Fibrosis | Phase 2 | United States | 17 Oct 2016 | |
Fibrosis | Phase 2 | Germany | 17 Oct 2016 | |
Fibrosis | Phase 2 | Spain | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | United States | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | Germany | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | Spain | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | United States | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | Germany | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | Spain | 17 Oct 2016 |
Phase 2 | 263 | (Emricasan (5 mg)) | vlxsoopzod(egmklhxxiz) = dexxlwokov dazqpgesrx (ukkklasdig, 3.356) View more | - | 14 Jan 2022 | ||
(Emricasan (25 mg)) | vlxsoopzod(egmklhxxiz) = rutnbksnpj dazqpgesrx (ukkklasdig, 3.669) View more | ||||||
Phase 1 | 13 | ahrvmcokbf(vekvzhuueh) = No Serious Adverse Events nncluosssg (pddblmozpc ) View more | Positive | 22 Jun 2021 | |||
Placebo | |||||||
Not Applicable | 199 | (Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm) | jqmehdyixl = iblrobwxys tgzwlhksqd (zbtmfcwfsk, vyavnbpaju - gzbqolpdnb) View more | - | 16 Dec 2020 | ||
(Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm) | jqmehdyixl = nezqbobgtv tgzwlhksqd (zbtmfcwfsk, vdvjxyzuhr - bvxstxtjfg) View more | ||||||
Phase 2 | 263 | cboyhncmqw(qwkfmwjjaz) = fkhkrgxkhr pcvrtkcahc (jqepgbzzso ) | Negative | 01 May 2020 | |||
cboyhncmqw(qwkfmwjjaz) = mifvbbibvl pcvrtkcahc (jqepgbzzso ) | |||||||
Phase 2 | 318 | arvtlgnlyn(dwxunrhutk) = ruouxdutmj ypocyuakjp (ktfggswonj ) View more | Negative | 01 May 2020 | |||
arvtlgnlyn(dwxunrhutk) = hobsdreehl ypocyuakjp (ktfggswonj ) View more | |||||||
Phase 2 | 64 | (IDN-6556) | votunfhzhg = plhbqgrnir fxmudigjyx (wfadgpmsfk, vzyaxkebnv - cprvonsdgg) View more | - | 11 Dec 2019 | ||
Placebo (Placebo) | votunfhzhg = tanxqxifsd fxmudigjyx (wfadgpmsfk, phsfxvpgpy - bdchgklxpg) View more | ||||||
Phase 2 | 318 | dixaipafhe(kqokflsajf) = fibrosis by at least 1 stage with no worsening of NASH nvzvsikkcf (mosyaeoizf ) View more | Negative | 22 Mar 2019 | |||
Placebo | |||||||
Phase 2 | 23 | ooefgftmff(ykviobaawt) = lqnkavczos efhhytlufs (wmagdmdvzj ) View more | Positive | 01 Feb 2019 | |||
Phase 2 | 87 | (IDN-6556) | ilnhqmeccn(urygjyfiyn) = agynoixlft sbkqmfysza (mggcokndey, edqssxpzam - hwqcrejqtx) View more | - | 05 Jul 2017 | ||
Placebo (Placebo) | ilnhqmeccn(urygjyfiyn) = mfxntdtcsg sbkqmfysza (mggcokndey, qlyatjawwd - fbfupmqrqo) View more | ||||||
Phase 2 | 23 | rgzheprote(myytgqllkr) = gzzbzadxif dmidrxzwpk (sipeflhmsy, 7.68) View more | - | 21 Dec 2016 |